Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Total Revenues (First Half 2025) $3.2 million, an increase of $0.9 million (39%) year-over-year. This increase was primarily driven by strong seed sales from the subsidiary, Casterra.
Research and Development Expenses (First Half 2025) $4.8 million, a decrease of $1.7 million (26%) year-over-year. This decrease is primarily due to reduced R&D activities at Biomica and the discontinuation of operations at Canonic.
Sales and Marketing Expenses (First Half 2025) $800,000, a decrease of $300,000 (27%) year-over-year. The reduction reflects lower headcount across several subsidiaries.
Total Operating Expenses (First Half 2025) $7.7 million, a decrease of $3.4 million (31%) year-over-year. This significant decrease is mainly attributed to the reduced level of activity in subsidiaries.
Cash and Short-Term Bank Deposits (End of First Half 2025) $11.7 million. This does not include expected proceeds from the sales of Lavie Bio's assets and MicroBoost AI for Ag.
Revenues (Second Quarter 2025) $0.9 million, an increase of $0.3 million (50%) year-over-year. This increase was primarily driven by higher revenues recognized by Casterra attributed to seed sales.
Operating Loss (First Half 2025) $6.1 million, a decrease of $3.3 million (35%) year-over-year. This decrease is mainly due to decreased operating expenses.
Net Loss (First Half 2025) $7.7 million, a decrease of $2.1 million (21%) year-over-year. This decrease was primarily due to decreased operating expenses and increased financing income, partially offset by increased loss from operations held for sale and reduced revenues.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ChemPass AI: Evogene has completed version 1 of its generative AI foundation model for small molecule design in collaboration with Google Cloud. This model enhances ChemPass AI's capabilities in identifying novel molecules for pharma and agriculture.
Casterra: Casterra has entered new markets and marketing channels, showing strong potential for sustainable revenue growth.
Cost Reduction: Evogene executed a cost reduction plan, reducing R&D expenses by $1.7 million and sales/marketing expenses by $0.3 million in the first half of 2025. Workforce reductions included 40% at AgPlenus and 30% at Evogene.
Cash Flow Enhancement: Evogene sold Lavie Bio's activities and MicroBoost AI for Ag to ICL for $18.75 million, significantly improving cash flow.
Strategic Shift: Evogene is focusing on its ChemPass AI platform for small molecule innovation in pharma and agriculture. It integrated AgPlenus into Evogene and reduced activities in Biomica and Lavie Bio.
Pharma Collaboration: Evogene partnered with Tel Aviv University to develop small molecule therapeutics targeting diseases caused by metabolite accumulation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Risks: The ongoing war between Israel, Hamas, and Hezbollah, as well as potential escalations in Israel's northern border, poses significant risks to the company's operations and overall stability.
Strategic Execution Risks: The company is undergoing a strategic shift, including the sale of major assets and restructuring efforts, which involve significant workforce reductions (30% at Evogene, 40% at AgPlenus). These changes could disrupt operations and delay strategic goals.
Financial Risks: Despite cost reductions and asset sales, the company has a limited operational runway of approximately 18 months, raising concerns about long-term financial sustainability.
Subsidiary Performance Risks: Several subsidiaries, including Biomica and Lavie Bio, are scaling back operations or focusing on limited activities, which could impact revenue streams and strategic objectives.
Market and Revenue Risks: Revenue growth is primarily driven by seed sales from Casterra, but other subsidiaries like AgPlenus have seen revenue declines, particularly from reduced licensing agreements.
Operational Risks: The company is heavily reliant on its ChemPass AI platform for future growth, and any delays or failures in its development or commercialization could significantly impact its strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ChemPass AI Platform: Evogene is focusing on its ChemPass AI platform for accelerating small molecule-based innovation in pharma and agriculture. The platform will serve two key verticals: pharma for small molecule therapeutics and agriculture for crop protection products. The company plans to continue advancing the platform's technology, including partnerships with global tech leaders like Google.
Pharma Vertical: Evogene is establishing a partner ecosystem in pharma, including academic and industry collaborations in Israel and internationally. A dedicated business development arm will be created to accelerate growth in this vertical.
Agriculture Vertical: AgPlenus will continue strategic collaborations with Bayer and Corteva, with expectations for further growth and new partnerships later in 2025.
Subsidiary Focus: Lavie Bio will maintain its existing collaboration agreement and distribute funds to shareholders. Biomica will focus on completing its clinical trial by early 2026 and securing partners for development programs. Casterra will continue operations, entering new markets and marketing channels to build a sustainable revenue stream.
Financial Position: Evogene has a solid financial foundation with an operational runway of approximately 18 months. The company raised $4.4 million in June 2025 and completed a transaction with ICL, generating $15.25 million from Lavie Bio's activity sale and $3.5 million from MicroBoost AI for Ag.
Cost Reduction: The company implemented significant cost reductions, including a 30% workforce reduction at Evogene and a 40% reduction at AgPlenus. These changes are expected to reflect in financial reports starting Q3 2025.
Revenue Growth: Casterra's seed sales drove revenue growth in the first half of 2025. The company anticipates continued revenue growth through new market entries and business initiatives.
Clinical Trial Completion: Biomica is expected to complete its clinical trial by early 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much castor seed inventory do you have today, both finished and expected to be finished after the harvest? And if your current customer does not place a follow-on order, what are your plans to commercialize this inventory?
A:Ofer Haviv stated that they have a few hundreds of tons of castor seed inventory ready. They plan to sell these seeds to partners or use them to grow castor themselves and sell the grains. Field trials in Brazil and Kenya have shown promising results for their growth protocols.
Q:What steps need to occur before you can announce a castor oil business?
A:Ofer Haviv explained that they are focusing on grain cultivation and selling grain to partners rather than entering the oil business. The bottleneck is in castor cultivation, and their unique variety and growth protocols aim to address this demand competitively. Results from commercial field trials will be key.
Q:The stock is still low. When will it start going up?
A:Ofer Haviv mentioned that stock market movements are uncontrollable, but they are finalizing a new company strategy and presentation to be launched in September. They plan to announce new collaboration agreements in pharma and agriculture, which they believe will positively impact the stock.
Q:How representative are operating expenses in Q2 2025 or going forward operations? Are all cost reductions fully reflected in the numbers?
A:Ofer Haviv confirmed that cost reductions are fully reflected and expects continued decline in expenses across R&D, business development, marketing, sales, and G&A in the third and fourth quarters.
Q:What was revenue in Q2 '25? How should we think about peak sales given recent results? And how long should it take to reach peak sales?
A:Ofer Haviv stated that Casterra is the only activity producing regular sales, focusing on selling seeds and eventually grain. They are in advanced stages of validating their cost-effective growth protocols in Brazil and Africa, with promising initial results in Brazil. More information will be disclosed in upcoming quarters.
Q:For ChemPass AI platform, what catalyst milestones should we expect in the next 12 to 18 months to evaluate progress?
A:Ofer Haviv highlighted two types of catalysts: new collaborations with partners in pharma and agriculture, and advancements in the ChemPass AI engine. They are working with partners like Google to develop breakthrough capabilities, and recent developments have positively impacted discussions with potential partners.
Q:Review of Unclear Management Responses
A:Management avoided disclosing the specific amount of castor seed inventory and provided a general response about their plans. Additionally, the response to the question about stock price movement was vague, focusing on future plans and strategy rather than providing concrete timelines or assurances.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Ag
AgPlenus
Aviv University
CEO
CFO result
ChemPass AI
Google
ICL
Israel
MicroBoost AI
Ofer
Securities
Tel Aviv
activity
agriculture
collaboration
direction
effort
event
expectation
line
metabolite
molecule therapeutic
partner
pharma
plan
platform
priority
product
reduction headcount
remainder
sale
security
self assembly
streamlining
subsidiary
transaction
vertical
workforce reduction
EVGN Transcript
Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call reveals declining revenues, increased costs, and significant operating and net losses, indicating financial struggles. Despite cost reductions, the lack of clear guidance and vague responses during the Q&A, particularly regarding financial terms and timelines, adds uncertainty. The promising strategic shifts and partnerships, including with Google, are overshadowed by the immediate financial challenges. The market is likely to react negatively in the short term due to these concerns, leading to a predicted stock price movement in the negative range of -2% to -8%.
Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript
Positive11-20
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
Evogene Ltd. (EVGN) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
Evogene Ltd. (NASDAQ:EVGN) Q1 2025 Earnings Call Transcript
Unknown5-22
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
EVGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
